U.S. Markets open in 3 hrs 34 mins

Was Fibrocell Science Inc’s (FCSC) Earnings Growth Better Than Industry?

Cole Patterson

Examining Fibrocell Science Inc’s (NASDAQ:FCSC) past track record of performance is an insightful exercise for investors. It allows us to reflect on whether or not the company has met or exceed expectations, which is a great indicator for future performance. Today I will assess FCSC’s latest performance announced on 30 September 2017 and compare these figures to its longer term trend and industry movements. View our latest analysis for Fibrocell Science

Were FCSC’s earnings stronger than its past performances and the industry?

For the most up-to-date info, I use data from the most recent 12 months, which either annualizes the most recent 6-month earnings update, or in some cases, the most recent annual report is already the latest available financial data. This enables me to analyze different companies in a uniform manner using the latest information. For Fibrocell Science, the latest twelve-month earnings -$27M, which, in comparison to the prior year’s level, has become less negative. Since these values are somewhat myopic, I have calculated an annualized five-year value for FCSC’s earnings, which stands at -$25M. This means that, Fibrocell Science has historically performed better than recently, even though it seems like earnings are now heading back towards to right direction again.

NasdaqCM:FCSC Income Statement Nov 30th 17

We can further examine Fibrocell Science’s loss by researching what’s going on in the industry along with within the company. Firstly, I want to quickly look into the line items. Revenue growth over past couple of years has grew by 20.30%, signalling that Fibrocell Science is in a high-growth period with expenses shooting ahead of high top-line growth rates. Eyeballing growth from a sector-level, the US biotechnology industry has been growing, albeit, at a subdued single-digit rate of 8.45% over the previous year, and a substantial 22.54% over the past couple of years. This means that, though Fibrocell Science is currently running a loss, it may have benefited from industry tailwinds, moving earnings in the right direction.

What does this mean?

Fibrocell Science’s track record can be a valuable insight into its earnings performance, but it certainly doesn’t tell the whole story. Companies that incur net loss is always hard to predict what will happen in the future and when. The most valuable step is to examine company-specific issues Fibrocell Science may be facing and whether management guidance has dependably been met in the past. I recommend you continue to research Fibrocell Science to get a better picture of the stock by looking at:

1. Future Outlook: What are well-informed industry analysts predicting for FCSC’s future growth? Take a look at our free research report of analyst consensus for FCSC’s outlook.

2. Financial Health: Is FCSC’s operations financially sustainable? Balance sheets can be hard to analyze, which is why we’ve done it for you. Check out our financial health checks here.

3. Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
To help readers see pass the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned.